VRAX Company Profile and Key Details

VRAX has shown weak momentum, losing -16.37% over the past week and -53.01% over the past quarter, though year-to-date performance is down -17.29%. Short-term trend indicators are bullishly aligned (SMA20 -4.69%, SMA50 -26.25%, SMA200 -64.35%). The stock’s 14-day RSI is 41.03 (neutral), while the ATR of 0.03 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -88.05% below its high and over 10.56% above its low. Average 10-day trading volume of 12.43 million shares is significantly above the 3-month average of 2.27 million, indicating heightened recent market interest.

Virax Biolabs Group Limited (NASDAQ:VRAX) closed at $4.07 USD, losing -$0.01 (-0.25%) from the previous close of $4.08. The stock is currently mid-range between its 52-week high and low $2.50 and $28.50. With a market capitalization of about $759.56 thousand, Virax Biolabs Group Limited is classified as a micro-cap and shows higher-than-market volatility (beta ~1.33). Key stats such as the average daily volume over the past year has been around 2.05 million shares, volume is running light vs its 52-week average. Headquartered in Lanarkshire, SC, Virax Biolabs Group Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO James Foster, the company employs approximately 26 people and listed since July 21, 2022. Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases.

Virax Biolabs Group Limited generated EPS of -$1.25 over the past year. Five-year average earnings growth is -21.07%. Wall Street analysts project EPS growth of 57.19% annually over the next five years. The latest quarter delivered EPS of -$0.76. The next quarter is forecast at -$0.10. Next year's EPS is expected at $68.42. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.00 to $3.00. The high target offers -26.29% upside. The low target suggests -26.29% downside. The mean target is $3.00. This offers -26.29% upside. Virax Biolabs Group Limited earnings surprise history is a mixed track record. The quarter that ended November 01, 2025, missed forecasts by 123.08%.

Virax Biolabs Group Limited has 4.34 million shares outstanding. The public float is 3.68 million shares, elevated short interest at 8.99% of float. This equals 350.86 thousand shares. The short ratio is 0.31 days. Institutional investors hold 4.7% of the float. Insiders own 1.79%.

Virax Biolabs Group Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.69. This means the shares are trading below this model’s fair value.

Virax Biolabs Group Limited trades at a P/E ratio of -0.25, slightly below the S&P 500 average, with a price-to-sales ratio of 63.8 and a price-to-book ratio of 0.34 suggesting the stock is closer to book value. The P/FCF stands at -0.16, also above market averages.

Our AI price prediction model suggests that Virax Biolabs Group Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -26.04%, with price expected at $3.01 by July 27, 2026, within a range of $1.98 to $4.01 3-Month Outlook: Projected fall of -66.83%, reaching $1.35 by October 08, 2026, with a range of $0.76 to $2.30. 1-Year Outlook: Projected loss of -84.52%, with price at $0.63 by July 13, 2027, within a range of $0.00 to $1.75.

Virax Biolabs Group Limited (NASDAQ:VRAX) shares are down -17.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Virax Biolabs Group Limited trading at a premium to the broader market with a P/E of -0.25. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $3.00, suggesting -26.29% downside. Our AI forecast model points to short-term weakness (-26.04% over two weeks), a medium-term fall (-66.83% over three months), and a longer-term loss (-84.52% over one year), with expected trading ranges indicating moderate volatility.